0001209191-19-017835.txt : 20190307
0001209191-19-017835.hdr.sgml : 20190307
20190307172044
ACCESSION NUMBER: 0001209191-19-017835
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190306
FILED AS OF DATE: 20190307
DATE AS OF CHANGE: 20190307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Soteropoulos Paula
CENTRAL INDEX KEY: 0001692444
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38137
FILM NUMBER: 19666788
MAIL ADDRESS:
STREET 1: 49 WINONA STREET
CITY: PEABODY
STATE: MA
ZIP: 01960
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AKCEA THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001662524
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 472608175
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 22 BOSTON WHARF RD
STREET 2: 9TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 617-207-0202
MAIL ADDRESS:
STREET 1: 22 BOSTON WHARF RD
STREET 2: 9TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-03-06
0
0001662524
AKCEA THERAPEUTICS, INC.
AKCA
0001692444
Soteropoulos Paula
C/O AKCEA THERAPEUTICS, INC.
22 BOSTON WHARF ROAD, 9TH FLOOR
BOSTON
MA
02210
1
1
0
0
Chief Executive Officer
Common Stock
2019-03-06
4
M
0
18386
6.48
A
18386
D
Common Stock
2019-03-06
4
S
0
18386
32.1362
D
0
D
Stock Option (right to buy)
6.48
2019-03-06
4
M
0
18386
0.00
D
2025-12-15
Common Stock
18386
1742866
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The weighted average sale price for the transaction reported was $32.1362, and the range of prices were between $32.11 and $32.50. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
The shares vest as follows: 1/4th of the shares vest one year after January 1, 2015;1/48th of the shares vest monthly thereafter over the next three years.
/s/ Paula Soteropoulos
2019-03-07